» Articles » PMID: 19209957

Active-site Inhibitors of MTOR Target Rapamycin-resistant Outputs of MTORC1 and MTORC2

Overview
Journal PLoS Biol
Specialty Biology
Date 2009 Feb 13
PMID 19209957
Citations 600
Authors
Affiliations
Soon will be listed here.
Abstract

The mammalian target of rapamycin (mTOR) regulates cell growth and survival by integrating nutrient and hormonal signals. These signaling functions are distributed between at least two distinct mTOR protein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to the selective inhibitor rapamycin and activated by growth factor stimulation via the canonical phosphoinositide 3-kinase (PI3K)-->Akt-->mTOR pathway. Activated mTORC1 kinase up-regulates protein synthesis by phosphorylating key regulators of mRNA translation. By contrast, mTORC2 is resistant to rapamycin. Genetic studies have suggested that mTORC2 may phosphorylate Akt at S473, one of two phosphorylation sites required for Akt activation; this has been controversial, in part because RNA interference and gene knockouts produce distinct Akt phospho-isoforms. The central role of mTOR in controlling key cellular growth and survival pathways has sparked interest in discovering mTOR inhibitors that bind to the ATP site and therefore target both mTORC2 and mTORC1. We investigated mTOR signaling in cells and animals with two novel and specific mTOR kinase domain inhibitors (TORKinibs). Unlike rapamycin, these TORKinibs (PP242 and PP30) inhibit mTORC2, and we use them to show that pharmacological inhibition of mTOR blocks the phosphorylation of Akt at S473 and prevents its full activation. Furthermore, we show that TORKinibs inhibit proliferation of primary cells more completely than rapamycin. Surprisingly, we find that mTORC2 is not the basis for this enhanced activity, and we show that the TORKinib PP242 is a more effective mTORC1 inhibitor than rapamycin. Importantly, at the molecular level, PP242 inhibits cap-dependent translation under conditions in which rapamycin has no effect. Our findings identify new functional features of mTORC1 that are resistant to rapamycin but are effectively targeted by TORKinibs. These potent new pharmacological agents complement rapamycin in the study of mTOR and its role in normal physiology and human disease.

Citing Articles

Targeting mTOR Kinase with Natural Compounds: Potent ATP-Competitive Inhibition Through Enhanced Binding Mechanisms.

Marafie S, Alshawaf E, Al-Mulla F, Abubaker J, Mohammad A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770519 PMC: 11677242. DOI: 10.3390/ph17121677.


mTORC1, the maestro of cell metabolism and growth.

He L, Cho S, Blenis J Genes Dev. 2024; 39(1-2):109-131.

PMID: 39572234 PMC: 11789495. DOI: 10.1101/gad.352084.124.


Effects of Target of Rapamycin and Phosphatidylinositol 3-Kinase Inhibitors and Other Autophagy-Related Supplements on Life Span in Male .

Bearden A, Stewart E, Casher C, Shaddix M, Nobles A, Mockett R Int J Mol Sci. 2024; 25(21).

PMID: 39519056 PMC: 11547029. DOI: 10.3390/ijms252111504.


Molecular Characteristics of Aberrant Gene Mutations and Expression Profiles Induced by Benzo(a)pyrene in Hepatocellular Carcinoma Cells.

Cao X, Zhu Y, Cheng S, Zhang K, Wang H, Ba Q Toxics. 2024; 12(7).

PMID: 39058151 PMC: 11280947. DOI: 10.3390/toxics12070499.


A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC.

Goto Y, Koshizuka K, Ando T, Izumi H, Wu X, Sato K Cancer Res Commun. 2024; 4(7):1850-1862.

PMID: 38954773 PMC: 11284272. DOI: 10.1158/2767-9764.CRC-24-0247.


References
1.
Ruggero D, Grisendi S, Piazza F, Rego E, Mari F, Rao P . Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science. 2003; 299(5604):259-62. DOI: 10.1126/science.1079447. View

2.
Guertin D, Stevens D, Thoreen C, Burds A, Kalaany N, Moffat J . Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006; 11(6):859-71. DOI: 10.1016/j.devcel.2006.10.007. View

3.
Kumar A, Harris T, Keller S, Choi K, Magnuson M, Lawrence Jr J . Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol. 2007; 28(1):61-70. PMC: 2223287. DOI: 10.1128/MCB.01405-07. View

4.
Karim M, Hughes J, Warwicker J, Scheper G, Proud C, McCarthy J . A quantitative molecular model for modulation of mammalian translation by the eIF4E-binding protein 1. J Biol Chem. 2001; 276(23):20750-7. DOI: 10.1074/jbc.M011068200. View

5.
Knight Z, Gonzalez B, Feldman M, Zunder E, Goldenberg D, Williams O . A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006; 125(4):733-47. PMC: 2946820. DOI: 10.1016/j.cell.2006.03.035. View